Kariya Pharmaceuticals

Kariya Pharmaceuticals is a private, preclinical-stage biotech targeting a high-unmet need in neurodegenerative diseases with a novel dual incretin receptor agonist approach. Its lead asset, KP405, is positioned as a first-in-class, potentially superior therapy to existing incretin analogues, with completed GLP toxicology studies paving the way for Phase I trials. The company leverages strong scientific foundations from its CSO, a key opinion leader in neuroprotective incretin research, and strategic operational support from its CEO, who is an Executive-in-Residence at Novo Holdings. Backed by significant Danish institutional grants, Kariya aims to deliver a disease-modifying treatment for Parkinson's Disease.

Development of dual incretin receptor co-agonists (GLP-1/GIP) that exert neuroprotective effects through multiple mechanisms including enhancing synaptic plasticity, reducing neuroinflammation, promoting mitochondrial biogenesis, and inducing neurogenesis.

The neuroprotective incretin space is competitive, with several biotech and large pharma companies (e.g., Novo Nordisk, Eli Lilly) investigating GLP-1, GIP, and glucagon receptor agonists for neurodegenerative diseases. Kariya's differentiation lies in its specific dual GLP-1/GIP co-agonist approach and its focus on demonstrating superiority over single agonists.